Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma

计划入组 40 人 · 首次发布于 2017 年 5 月 4 日

A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma

计划入组 479 人 · 首次发布于 2019 年 1 月 14 日

Fruquintinib Combined With Sintilimab as Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

计划入组 29 人 · 首次发布于 2022 年 11 月 23 日

LGR5 modulators (esophageal adenocarcinoma)

Gastro-Oesophageal Reflux Therapy (Nycomed)

Cellspan Esophageal Implant

AUSTRALASIAN GASTRO-INTESTINAL TRIALS GROUP

Australia

White River Junction Veterans Affairs Medical Center

United States

Lucid Diagnostics

United States

Infinitopes Doses First Patient in Phase I/IIa Trial of Off-the-Shelf Cancer Vaccine ITOP1 for Resectable Esophageal Adenocarcinoma

Eli Lilly's Ramucirumab Shows Promise in Expanding Treatment Portfolio for Laryngeal Cancer

Innovent's IBI343 Receives Breakthrough Therapy Designation in China for Advanced Pancreatic Cancer